Hybridoma Monoclonal

Antibody Service

Mouse monoclonal antibody is used to fuse myeloma cells with activated B lymphocytes by cell technology to obtain hybridoma cells, which can secrete monoclonal antibody against a single antigen determination cluster. The antibodies have high specificity, stable passage, and can be large-scale repeated production, which is widely used in basic research, clinical diagnosis and new drug development.

With years of experience in monoclonal antibody research and development and a complete antibody production line, Clongene can provide you with one-stop customized services from antigen design, animal immunization, fusion screening to antibody production, and ultimately deliver high-quality monoclonal antibodies aligned with the clients application requirements, and meeting clients different needs.

Botin Technology is a high-tech enterprise based in Singapore. We are specializing in the R&D, production and sales of biological raw materials and IVD reagents. In addition, we can also provide CRO/CDMO services. As a well-known global supplier of biological raw materials, we provide products and services to major IVD products manufactures and scientific research institutions.  Our main IVD reagents have obtained authoritative certifications including FDA 510(k) clearances of US, TGA of Australia, CE of EU  and some other certifications from different countries. The products have been sold well in more than 100 countries and regions around the world.  We can also provide customers with high-quality CRO/CDMO services, including protein expression services, antibody discovery services, antibody expression services and stable cell line development service. While continuously innovating the products, we always commit to product innovation and strict quality control. We pursue to provide our customers with high-quality products and excellent service through infinite trust and responsibility.

Service Advantages

·   Multiple antigens optional: provide proteins, DNA, peptides, cells and other antigens.

·   Rapid immunization: multiple immunization regimens, as soon as 21 days to complete immunization.

·   High fusion efficiency: optimized electrofusion technology, significantly improved hybridoma cell fusion rate.

·   Rich development experience: over 1000 hybridoma development experience.

·   Customizable services: comprehensive services from antigen expression to hybridoma antibody development and     antibody production can be tailored for each customer to meet the special needs of each customer.